STAT3 and neoplasm: Pharmacologic inhibition of STAT3 via administration of C188-9 also improved the response of NSCLC xenografts to cisplatin and vinblastine, and significantly reduced tumor growth in the combination-treated group compared to mice treated with single agent chemotherapies [273].